Targeting thiol isomerase activity with zafirlukast to treat ovarian cancer from the bench to clinic.
Gelzinis JA, Szahaj MK, Bekendam RH, Wurl SE, Pantos MM, Verbetsky CA, Dufresne A, Shea M, Howard KC, Tsodikov OV, Garneau-Tsodikova S, Zwicker JI, Kennedy DR.
Gelzinis JA, et al.
FASEB J. 2023 May;37(5):e22914. doi: 10.1096/fj.202201952R.
FASEB J. 2023.
PMID: 37043381
Free PMC article.